This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The compliance in patients using a 3-and 5-day course of azithromycin (58.0% and 42.9% respectively) (P<0.01) was better than a 10-day course of roxithromycin (7.5%) (P<0.05). The time to resolution of symptoms for a 3-and 5-day course of azithromycin (4.1 days and 5 days respectively) (P<0.01) was faster than a 10-day course of roxithromycin (7.5 days) (P<0.05). The confidence interval was 99% for a 3-and 5-day course of azithromycin and 95% for a 10-day roxithromycin course.
In terms of side effects, the incidence of diarrhoea in patients treated with a 3-and 5-day course of azithromycin (8.8% and 7.1% respectively) (P<0.01) was lower than a 10-day course of roxithromycin (15.8%) (P<0.05). The incidence of dyspepsia in patients prescribed with a 3-and 5-day course of azithromycin (14.3 and 16.7 respectively) (P<0.01) was greater than a 10-day course of roxithromycin (12.2%). The incidence of nausea in patients using 3-and 5-day treatment of azithromycin (15.4% and 19.1% respectively) was greater than a 10-day course of roxithromycin (15.6%) (P<0.05).
Clinical conclusions
The use of 3-and 5-day course of azithromycin lead to better clinical outcomes in terms of compliance and resolution of symptoms than a 10-day course of roxithromycin.
Measure of benefits used in the economic analysis
Health outcomes used in the analysis were compliance rates, speed of resolution of symptoms, and side effects.
Compliance was recorded by a method based on the MEMS (Aprex Corporation) process. The time to resolution of symptoms was derived from patients' diaries based on a 10 cm visual analogue scale question and from a 2 week clinical evaluation based on semi-structured telephone interviews.
Direct costs
Quantities and costs were reported separately. Direct costs included physician visits, drugs, and laboratory tests. Costs of services and laboratory tests were based on official charges (UCANSS, 1992) and the costs of drugs were estimated from the Dictionnaire Vidal -1992.
Statistical analysis of costs
Bivariate analyses of health care utilization were performed with the chi-squared test and Student's t-test. Confidence intervals and p values were reported for some resources used.
Indirect Costs
Indirect costs were included as loss of earnings incurred by patients with pharyngitis. Costs and quantities were reported separately. Costs and quantities data were obtained from patients' charts and patient interviews.1992 price data was used.
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
In terms of side effects, the incidence of diarrhoea in patients treated with a 3-and 5-day course of azithromycin (8.8% and 7.1% respectively) (P<0.01) was lower than a 10-day course of roxithromycin (15.8%) (P<0.05). The incidence of dyspepsia in patients prescribed with a 3-and 5-day course of azithromycin (14.3 and 16.7 respectively) (P<0.01) was greater than a 10-day course of roxithromycin (12.2%). The incidence of nausea in patients using a 3-and 5-day course of azithromycin (15.4% and 19.1% respectively) was greater than a 10-day course of roxithromycin (15.6%) (P<0.05).
Cost results
The total treatment costs of a 3-and 5-day course of azithromycin were $193.60 and $195.30 per patient respectively. The total costs of using roxithromycin was $202.10 per patient. The cost saving of azithromycin versus a 10-day course of roxithromycin were $8.50 (for a 3-day course) and $6.80 (for a 5-day course) per patient.
